Transforming growth factor b (TGF-b) has been considered as a candidate for gene therapy of orthopedic diseases. The possible application of cell-mediated TGF-b gene therapy as a new treatment regimen for degenerative arthritis was investigated. In this study, fibroblasts expressing active TGF-b1 were injected into the knee joints of rabbits with artificially made cartilage defects to evaluate the feasibility of this therapy for orthopedic diseases. Two to 3 weeks after the injection there was evidence of cartilage regeneration, and at 4 to 6 weeks the cartilage defect was completely filled with newly grown hyaline cartilage. Histological analyses of the regenerated cartilage suggested that it was well integrated with the adjacent normal cartilage at the sides of the defect and that the newly formed tissue was indeed hyaline cartilage. Our findings suggest that cell-mediated TGF-b1 gene therapy may be a novel treatment for orthopedic diseases in which hyaline cartilage damage has occurred.
INTRODUCTION I
N THE ORTHOPEDIC FIELD, some cytokines are being considered as suitable candidates for the treatment of orthopedic diseases. For example, bone morphogenic proteins (BMPs) have been identified as effective stimulators of bone formation (Zegzula et al., 1997; Louwerse et al., 2000; Sellers et al., 2000) . Analogously, transforming growth factor b proteins (TGF-bs) have been reported to induce osteogenesis and chondrogenesis (Sporn and Roberts, 1988; Joyce et al., 1990) . TGFb is considered to be a multifunctional cytokine, playing a regulatory role in cell growth, differentiation, and extracellular matrix protein synthesis (Sporn and Roberts, 1988) . TGF-b inhibits the growth of epithelial cells and osteoclast-like cells in vitro (Chenu et al., 1988) , but stimulates endochondral ossification and eventually bone formation in vivo (Matsumoto et al., 1994) . TGF-b-induced bone formation is mediated by stimulating the growth of subperiosteal pluripotential cells, which eventually differentiate into cartilage-forming cells (Miettinen et al., 1994) . The results of studies have suggested that TGF-b stimulated chondrocyte proteoglycan synthesis (van Beuningen et al., 1994; van Osch et al., 1998) and the growth of articular chondrocyte cells (Yonekura et al., 1999) .
The therapeutic value of the TGF-b protein in orthopedics has been reported (Lind et al., 1993; Critchlow et al., 1995; Ripamonti et al., 1997; Glansbeek et al., 1998) . However, widespread clinical applications of this protein have been limited because of its short-term effects, resulting from its short halflife, and high cost. There have been reports of articular carti-lage regeneration after the transplantation of autologous cartilage cells that were expanded in culture (Brittberg et al., 1994) . However, this procedure entails two operations with an excision of the soft tissues and requires a lengthy recovery time, at least 9 to 12 months. Other growth factors, such as epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), and insulin-like growth factor I (IGF-I), have also been tested for their stimulating effects on chondrogenesis in vivo, but none have showed any effect on healing standard cartilage defects (Neidel, 1992) . A collagen sponge impregnated with a recombinant human BMP implanted in the knees of rabbits with a full-thickness defect showed a 70% repair of the defect at 24 weeks posttreatment (Sellers et al., 1997) . Despite the promising results, this treatment still requires an operation and a long regeneration time. Therefore, a new method for the long-term and cost-effective delivery of such cytokines is essential.
Degenerative arthritis is the most frequently encountered orthopedic disease associated with cartilage damage. Almost every joint in the body, such as the knee, the hip, the shoulder, and the wrist, is susceptible to cartilage damage. The pathogenesis of this disease is the degeneration of the hyaline articular cartilage, which becomes deformed, fibrillated, and eventually excavated during the course of degenerative arthritis (Mankin, 1982) . If the degenerated cartilage could somehow be regenerated, most patients would be able to enjoy their lives without debilitating pain.
A cell-mediated TGF-b1 gene therapeutic approach for regenerating the hyaline cartilage in knee joints of rabbits with artificially made cartilage defects was tested. Here we report that NIH 3T3 fibroblasts containing a transgene, TGF-b1, showed sustained TGF-b1 expression and induced the proliferation and differentiation of the existing chondrocytes and/or chondrocyte precursors residing in the defect base, which resulted in the complete regeneration of hyaline cartilage in 6 weeks.
MATERIALS AND METHODS

DNA and virus construction
pMTMLVb1 was constructed by cloning a 1.2-kb porcine TGF-b1 cDNA into the polylinker site of the replication-defective retroviral vector pMTMLV. pMTMLV vector was derived from the retroviral vector MFG by deleting entire gag and env sequences as well as some of the c packaging sequence. All of the U3 of 59 long terminal repeat (LTR) except for 36 bp at the 59 end was replaced with the metallothionein (MT) promoter (Kim et al., 1998) . pMTMLVb1 and pVSVG were cotransfected into GP293 cells by calcium phosphate method. After 48 hr of culture, the supernatant was filtered through a 0.45-mm pore size filter and the half of it was saved at 270°C for later use. NIH 3T3 cells seeded in 60-mm culture dishes 18 hr before infection were infected with the filtrate plus Polybrene (8 mg/ml; Sigma, St. Louis, MO). After 4 hr of incubation, medium was replaced with fresh medium. Infection was repeated 24 hr later with the saved viral supernatant. Transduced cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and selection with neomycin (100 mM/ml) started 48 hr after infection.
Northern blot analysis
Total RNA was isolated from cells by a guanidinium-isothiocyanate extraction protocol. Ten micrograms of RNA was electrophoresed on a 1.0% agarose gel containing 0.66 M formaldehyde, transferred to a Duralon-UV membrane, and then cross-linked with a UV Stratalinker (Stratagene, La Jolla, CA). Blots were prehybridized and hybridized in a solution (1% bovine serum albumin, 7% [w/v] sodium dodecyl sulfate [SDS], 0.5 M sodium phosphate, 1 mM EDTA) at 65°C. Hybridized blots were washed in 13 SSC (0.1% SDS) hybridized with 32 P-
FIG. 1.
Expression of TGF-b1 mRNA and the secretion rate of TGF-b1 protein in NIH 3T3-TGF-b1 fibroblasts. TGF-b1 cDNA sequence was cloned into the polylinker site of the replication-defective retroviral vector pMTMLV, under the control of the metallothionein promoter. NIH 3T3 fibroblasts were infected with recombinant TGF-b1 retroviruses. Stable cell lines were generated by neomycin selection and then subjected to Northern analysis (Miettinen et al., 1994) . (A) Northern analysis of mRNA extracted from TGF-b1-producing fibroblasts (NIH 3T3-TGF-b1) and control cells (NIH 3T3-neo). TGF-b1 transcript of NIH 3T3-TGF-b1 cells was elevated in the presence of 100 mM ZnSO 4 . (B) TGF-b1 protein secretion rate of NIH 3T3-TGF-b1 or NIH 3T3-neo cells was measured by ELISA in the presence or absence of ZnSO 4 . The average secretion rate of TGF-b1 of several stable cell lines was about 30 ng/10 6 cells per 24 hr. labeled cDNA probes for porcine TGF-b1. b-Actin was used as a control for the amount of sample loaded.
Intraarticular injection of TGF-b1-producing cells
New Zealand White rabbits weighing 2.0-2.5 kg were selected for the animal study. These rabbits were mature and had a tidemark. The knee joint was exposed and a partial cartilage defect (3 mm 3 6 mm, 1-2 mm deep) was made on the hyaline cartilage layer of the femoral condyle with a surgical knife. Caution was exercised to ensure that the subchondral bone was not damaged in the process. Either control NIH 3T3-neo cells or NIH 3T3-TGF-b1 cells were injected into the rabbit knee joint with a defect. These cells (0.5 ml, containing 2 3 10 6 cells/ml) were either injected intraarticularly after suturing, or [15] [16] [17] [18] [19] [20] 
Control
top of the defect. In the latter case, the cells were left in the defect for 15-20 min to allow the cells to permeate the wound before suturing. In both cases, no significant difference was observed in the regeneration of cartilage. This study was approved by the Institutional Animal Care and Use Subcommittee of the Inha University College of Medicine (Inchon, South Korea).
Histological staining
After harvesting the knee joints, the specimens were fixed in formalin and decalcified in nitric acid. Blocks of the specimens were embedded with paraffin and they were cut into 0.8-nmthick slices. The sections were stained with hematoxylin-eosin, Safranin O, toluidine blue, and Masson's trichrome for microscopic analyses of the regenerated cartilage.
MRI analysis
Magnetic resonance imaging (MRI) of the knee was performed with a 1.5-T magnet (Signa Horizon; General Electric Medical Systems, Milwaukee, WI) and a conventional extremity coil. One sequence was used to assess the articular cartilage in the oblique-axial plane. Each sequence consisted of fast spinecho images that were performed with a long repetition time (4000 msec) a short effective-echo time (108 msec), an echo train length of 12, a bandwidth of 16 kHz, and a slice thickness of 1.5 mm with no interslice gap. Oblique-axial images were obtained with a 256 by 224 matrix and a field of view of 8 cm. The scan time was 3.5 min.
RT-PCR analysis
Regenerated hyaline cartilage was removed from the femoral condyle 1, 2, 3, 4, 5, or 6 week(s) after injection of NIH 3T3-TGF-b1 or control NIH 3T3-neo cells and mRNA was extracted from the cartilage tissue each time. First-strand cDNA was synthesized by using reverse transcriptase (RT) with oligo(dT) primers and then the polymerase chain reaction (PCR) was performed with an LTR-specific primer (forward, 59-TCT TTC ATT TGG GGG CTC GTC-39) and TGF-b1-specific primer (reverse, 59-AGA GCA ATA CAG GTT CCG GCA C-39) for 35 cycles. Each cycle consists of a denaturation step at 94°C for 1 min, an annealing step at 56°C for 2 min, and an extension step at 72°C for 3 min. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. The set of primers for GAPDH included the following: forward primer (59-AAC TCC CTC AAG ATT GTC AGC A-39) and reverse primer (59-TCC ACC ACC CTG TTG CTG TA-39).
Immunohistochemical staining
Sections, prepared as described above, were deparaffinized and hydrated by sequential incubations in xylene and ethanol. After washing in 13 phosphate-buffered saline (PBS) for 2 min, the sections were blocked with 3% H 2 O 2 for 10 min. The primary antibody against TGF-b1, type I collagen (Novocastra, Newcastle upon Tyne, UK), type II collagen (Southern Biotechnology, Birmingham, AL), mouse proliferating cell nuclear antigen (PCNA; Serotec, Raleigh, NC), or mouse MHC class I protein (Accurate Chemical, Westbury, NY) was applied to the sections and incubated for 1 hr. The control sections were incubated in 13 PBS without the primary antibody at this step. The sections were washed and blocked with 5% milk in 13 PBS for 20 min before incubating with the horseradish peroxidase (HRP)-conjugated secondary antibody. The chromogen reaction was performed with 0.05% diaminobenzidine (DAB) in 13 PBS for 5 min. The sections were subsequently stained with hematoxylin and mounted.
RESULTS
Expression of TGF-b1 in NIH 3T3 fibroblasts
To explore the possibility of cell-mediated gene therapy using fibroblasts expressing TGF-b1 as a new treatment method for degenerative arthritis, NIH 3T3 murine fibroblast cells were infected with recombinant TGF-b1 retroviruses in which the expression of active TGF-b1 was driven by the metallothionein (MT) promoter. Several stable cell lines (NIH 3T3-TGF-b1) were generated by G418 selection and subsequent Northern analysis. An inducible promoter was chosen because a high level of constitutive expression of TGF-b1 might inhibit host cell growth. Most of the selected cell lines expressed the TGFb1 mRNA without zinc induction, but the level of transgene expression was markedly elevated when they were cultured in 100 mM zinc sulfate solution (Fig. 1) . These TGF-b1-producing cells maintained a high level of TGF-b1 expression for at least a few months in vitro. The average rate of secretion of TGF-b1, measured by enzyme-linked immunosorbent assay (ELISA), from these stable cell lines was about 30 ng/10 6 cells per 24 hr.
Regeneration of hyaline cartilage with TGF-b1-producing fibroblasts
To simulate degenerative arthritis of the knee joint, a partial cartilage defect (3 mm 3 6 mm, 1-2 mm deep) was made with a surgical knife in the hyaline cartilage layer of the femoral condyle of New Zealand White rabbits ( Fig. 2A) . NIH 3T3-TGF-b1 cells (5 3 10 5 to 2 3 10 6 ) were subsequently injected into the site of the defect. The same amount of NIH 3T3-neo cells containing the expression vector without the TGF-b1 gene was injected into the wounded contralateral knee joint to serve as a control. Cells were either injected into the knee joint immediately after suturing or loaded into the defective region 15-20 min before suturing. The level of cartilage regeneration did not differ significantly with these two approaches in several of the rabbits tested (data not shown).
The regeneration of hyaline cartilage was not obvious 1 week after injection of NIH 3T3-TGF-b1 cells (Fig. 2B, a and b) . At 3 weeks postinjection, most of the defect sites were filled with regenerated tissue (Fig. 2B, c and d) and at 6 weeks, the regeneration of hyaline cartilage in the defect was complete (Fig.  2B, e and f) . In contrast, no new hyaline cartilage was formed at the site of the cartilage defect of the contralateral knee injected with control NIH 3T3-neo fibroblasts at 6 weeks postinjection (Fig. 2B, g and h) . Regeneration of hyaline cartilage was not affected by the addition of zinc in the drinking water even though addition of zinc resulted in a marked increase in TGFb1 expression in vitro (data not shown). The relative degrees of hyaline cartilage regeneration 1, 3, and 6 week(s) after injection of NIH 3T3-TGF-b1 cells were determined by measuring the percentage of regenerated cartilage height relative to that of normal cartilage. The average percentages of cartilage regeneration 1, 3, and 6 week(s) after injection were 24, 69, and 98%, respectively (Fig. 3) . These statistical data also suggest that the regeneration of hyaline cartilage in the defect can be accomplished within 6 weeks after injection of the TGF-b1-producing cells. Overall, histological examinations demonstrated the regeneration of hyaline cartilage in 80% of NIH 3T3-TGF-b1 cell-treated animals at 3 to 6 weeks postinjection (n 5 40).
Histological examination of regenerated cartilage
To examine integration of newly generated cartilage with the adjacent normal cartilage, and its integrity and possibility of overgrowth, histological analyses with high-magnification, cartilage-specific stainings, and magnetic resonance imaging (MRI) observation, were performed. Four weeks after injection of NIH 3T3-TGF-b1 cells, microscopic examination of regenerated hyaline cartilage revealed that the cartilage was well integrated with the adjacent normal cartilage, although the architecture of the regenerated tissue was not fully developed into that of normal cartilage at this stage ( Fig. 4a and b) . PCNApositive cells were markedly increased in regenerated cartilage ( Fig. 4d and e) . At 6 weeks, staining of the regenerated cartilage with hematoxylin ( Fig. 4c) , Safranin O, toluidine blue, Masson's trichrome, type I collagen antibody, and type II collagen antibody revealed that chondrocytes in the regenerated tissue were fully differentiated (Fig. 5a-e) . The morphology and staining pattern of the regenerated tissue were the same as those of the adjacent normal hyaline cartilage, indicating that the newly generated tissue was indeed hyaline cartilage. These results suggest that the resulting repair of the defect is almost identical to the natural processes of hyaline cartilage formation. Histological examination of adjacent synovium, vascular channels, subchondral blood vessels, and bone showed no detectable alterations (data not shown). To evaluate the possibility of overgrowth of the regenerated hyaline cartilage in vivo, MRI examination of the knee joint was performed over 12 weeks after injection. MRI examination of the knee 6, 8, 10 weeks after injection of the NIH 3T3-TGF-b1 fibroblasts showed no signs of overgrowth. MRI pictures taken 12 weeks after injection of NIH 3T3-TGF-b1 or NIH 3T3-neo cells are shown in Fig. 6a and c, respectively. The same knee joints were also examined after sacrifice of the animals and confirmed the results of MRI observation (Fig. 6b and d) . The results of histological studies of the regenerated cartilage 12 weeks after injection indicated that the morphology and staining pattern were similar to those of the repaired cartilage at 6 weeks (data not shown).
Expression of exogenous TGF-b1 in vivo after injection
To investigate the expression of exogenous TGF-b1 transcript after injection of the TGF-b1-producing fibroblasts, RT-PCR was performed with mRNA extracted from the regenerated cartilage tissues up to 6 weeks postinjection. To detect exogenous TGF-b1 transcript only, a set of primers was derived from the retroviral LTR sequence and 59 end of the TGF-b1 gene of pMTMLVb1. Since a splicing event of the full-length retroviral transcript takes place at the splicing donor (SD) and splicing acceptor (SA) sites, located between the LTR and TGF-b1, the primer set generates two RT-PCR products (Fig. 7A) . One is from the unspliced transcript and the other is from the spliced transcript. The result showed that the expression of transgenic TGF-b1 mRNA peaked at 2 weeks and continued to 4 weeks after injection of the cells (Fig. 7B) . Immunohistochemical staining of regenerated hyaline cartilage performed with TGF-b1 antibody 3 weeks postinjection showed that a high level of TGF-b1 protein expression occurred only in the cells of the regenerated cartilage ( Fig. 7C and D) . No antibody staining was observed in a section of the same tissue probed with the secondary antibody alone (Fig. 7E ). This immunohistochemical staining result correlates well with the RT-PCR data. These RT-PCR and immunohistochemical staining results suggest that the long-term expression of transgenic TGFb1 mRNA can be obtained with the current cell-mediated TGFb1 gene therapy approach. This would prove useful in developing a gene therapy protocol that requires long-term production of a protein.
Fate of injected TGF-b1-producing fibroblasts
To investigate the fate of the injected NIH 3T3-TGF-b1 cells after injection, immunohistochemical staining of the regenerated cartilage with mouse-specific MHC class I antibody was performed. Only the cells in the regenerated tissue were stained with the mouse-specific MHC class I antibody. The staining result at 3 weeks postinjection is shown in Fig. 7F . The regenerated tissue was stained with the MHC class I antibody up to 4 weeks after injection and the positive MHC class I staining was not detected in the regenerated cartilage at 6 weeks postinjection (Fig. 7H) .
DISCUSSION
The results of this study suggest that cell-mediated TGF-b1 gene therapy may be a novel treatment for orthopedic diseases in which hyaline cartilage damage has occurred. Here it was demonstrated that fibroblasts containing an exogenous TGF-b1 gene are able to express the transgene for at least 4 weeks after injection in vivo. Furthermore, in a partial cartilage defect model, the TGF-b1 protein produced from the cells can induce a full regeneration of the hyaline cartilage tissue in 6 weeks.
The result of RT-PCR analysis of the regenerated tissues showed that the expression of exogenous TGF-b1 transcripts peaked at 2 weeks postinjection and lasted up to 4 weeks. This finding suggests that active TGF-b1 proteins secreted from the injected cells can be available for more than 4 weeks to help repair the cartilage defect in vivo. This sustained expression of active TGF-b1 protein is a key reason for such rapid regeneration of the cartilage shown in the present study. Sellers et al. (2000) demonstrated that a collagen sponge impregnated with 5 mg of recombinant human BMP-2 lasted for 2 weeks after implantation in vivo. Therefore, it would be difficult for these cytokines to be present for a sustained period of time in vivo without a repeated injection or implantation of purified proteins. The results of immunohistochemical staining of the tissue repaired with the TGF-b1 antibody correlated well with the RT-PCR data. The level of TGF-b1 protein expression was highest 3 weeks after injection ( Fig. 5c and d) . It became weaker at 4 weeks, and was absent 6 weeks after injection (data not shown).
The results of different cartilage-specific histological stainings demonstrated integration of the regenerated cartilage tissue with the normal adjacent cartilage even 3 to 4 weeks after injection of the TGF-b1-producing cells. Previous studies have suggested that integration of the repaired tissue was difficult since chondrocytes in the normal cartilage were not thought to be involved in repair (DePalma et al., 1966; Shapiro et al., 1993) . Our results indicated that TGF-b1 produced from the injected cells stimulated the chondrocytes and/or chondrocyte precursors in the remaining normal cartilage to proliferate and/or differentiate into normal chondrocytes. These results also showed that the overall architecture and morphology of the chondrocytes in the newly generated cartilage were similar to those of normal chondrocytes (Figs. 4 and 5) . Despite the histological staining data, the ability of the regenerated cartilage to withstand the mechanical forces within the joint still remains to be investigated.
The details of the molecular mechanism that controls the regeneration of hyaline cartilage with the present cell-mediated TGF-b1 gene therapy method are still not clear. However, the most likely mechanism is that the TGF-b1 secreted from the injected fibroblasts induces the proliferation and differentiation of the existing chondrocytes and/or chondrocyte precursors residing in the wound base. Immunohistochemical staining of the regenerated cartilage tissue with mouse MHC class I antibodies, shown in Fig. 7F , suggests that the injected fibroblast cells are gradually replaced by growth of the underlying rabbit cartilage.
Degenerative arthritis is the most frequently encountered disease with cartilage damage among the orthopedic diseases. The efficacy of the cytokines, including TGF-b, in inducing regeneration of the hyaline articular cartilage has been demonstrated previously. However, the clinical application of these cytokines has been limited because of its short half-life. The results of this study strongly support the feasibility of a cell-mediated gene therapy approach for achieving the long-term production of TGF-b1, using fibroblasts secreting TGF-b1 for cartilage repair. A cell-mediated cytokine gene therapy approach for cartilage regeneration does not require an operation or a lengthy rehabilitation time, whereas the autologous cell-based therapy (Brittberg et al., 1994) and cytokine protein-based therapy involve at least one operation and a substantial rehabilitation time (Sellers et al., 1997 (Sellers et al., , 2000 . Therefore, cell-mediated TGF-b1 gene therapy may be a clinically useful and efficient therapy for treating orthopedic diseases with hyaline cartilage damage.
